BG98194A - Фибриногенни рецепторни антагонисти - Google Patents

Фибриногенни рецепторни антагонисти Download PDF

Info

Publication number
BG98194A
BG98194A BG98194A BG9819493A BG98194A BG 98194 A BG98194 A BG 98194A BG 98194 A BG98194 A BG 98194A BG 9819493 A BG9819493 A BG 9819493A BG 98194 A BG98194 A BG 98194A
Authority
BG
Bulgaria
Prior art keywords
agent
mammal
pharmaceutically acceptable
administered
inhibiting
Prior art date
Application number
BG98194A
Other languages
Bulgarian (bg)
English (en)
Inventor
Mark Duggan
George Hartman
Melissa Egbertson
Nathan Ihle
Laura Turchi
Wiliam Hoffman
Original Assignee
Merck & Co. Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co. Inc. filed Critical Merck & Co. Inc.
Publication of BG98194A publication Critical patent/BG98194A/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Materials For Medical Uses (AREA)
BG98194A 1991-05-07 1993-11-02 Фибриногенни рецепторни антагонисти BG98194A (bg)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US69689391A 1991-05-07 1991-05-07
US72035791A 1991-06-25 1991-06-25
US87126292A 1992-04-23 1992-04-23
PCT/US1992/003463 WO1992019595A1 (fr) 1991-05-07 1992-04-27 Antagonistes de recepteur de fibrinogene

Publications (1)

Publication Number Publication Date
BG98194A true BG98194A (bg) 1994-09-30

Family

ID=27418643

Family Applications (1)

Application Number Title Priority Date Filing Date
BG98194A BG98194A (bg) 1991-05-07 1993-11-02 Фибриногенни рецепторни антагонисти

Country Status (20)

Country Link
US (2) US5281585A (fr)
EP (1) EP0512831B1 (fr)
JP (1) JP2531562B2 (fr)
KR (1) KR920021531A (fr)
CN (1) CN1067883A (fr)
AT (1) ATE184874T1 (fr)
AU (1) AU647618B2 (fr)
BG (1) BG98194A (fr)
CA (1) CA2068064C (fr)
DE (1) DE69230013T2 (fr)
ES (1) ES2137175T3 (fr)
FI (1) FI934894A0 (fr)
HU (1) HUT68769A (fr)
IE (1) IE921463A1 (fr)
IL (1) IL101779A0 (fr)
MX (1) MXPA92002103A (fr)
NO (1) NO933999L (fr)
NZ (1) NZ242609A (fr)
WO (1) WO1992019595A1 (fr)
YU (1) YU47992A (fr)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780303A (en) * 1990-04-06 1998-07-14 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5672585A (en) * 1990-04-06 1997-09-30 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US6521594B1 (en) 1990-04-06 2003-02-18 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US6017877A (en) * 1990-04-06 2000-01-25 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
WO1993018058A1 (fr) * 1992-03-06 1993-09-16 G.D. Searle & Co. Imitateurs peptidiques utiles comme inhibiteurs de l'agregation plaquettaire
WO1994012181A1 (fr) * 1992-12-01 1994-06-09 Merck & Co., Inc. Antagonistes des recepteurs du fibrinogene
DE4308034A1 (de) * 1993-03-13 1994-09-15 Cassella Ag Neue Heterocyclen, ihre Herstellung und ihre Verwendung
US5753659A (en) * 1993-03-29 1998-05-19 Zeneca Limited Heterocyclic compouds
US5652242A (en) * 1993-03-29 1997-07-29 Zeneca Limited Heterocyclic derivatives
GB9406143D0 (en) * 1993-03-29 1994-05-18 Zeneca Ltd Heterocyclic derivatives
CA2155307A1 (fr) * 1993-03-29 1994-10-13 Michael Garth Wayne Composes heterocycliques, inhibiteurs de l'agregation des plaquettes
US5750754A (en) * 1993-03-29 1998-05-12 Zeneca Limited Heterocyclic compounds
GB9313285D0 (en) * 1993-06-28 1993-08-11 Zeneca Ltd Acid derivatives
US5463011A (en) * 1993-06-28 1995-10-31 Zeneca Limited Acid derivatives
GB9313268D0 (en) * 1993-06-28 1993-08-11 Zeneca Ltd Chemical compounds
PT669912E (pt) * 1993-09-22 2002-03-28 Fujisawa Pharmaceutical Co Derivados de n-(3-piperidinil-carbonil)-beta-alanina como antagonistas de paf
EP0725059B1 (fr) * 1993-10-19 2001-01-17 Sumitomo Pharmaceuticals Company, Limited Derive d'acide 2,3-diaminopropionique
DE4427979A1 (de) * 1993-11-15 1996-02-15 Cassella Ag Substituierte 5-Ring-Heterocyclen, ihre Herstellung und ihre Verwendung
HUT74690A (en) * 1993-11-24 1997-01-28 Du Pont Merck Pharma Novel isoxazoline and isoxazole fibrinogen receptor antagonists process for producing them and pharmaceutical compositions containing them
US5523302A (en) * 1993-11-24 1996-06-04 The Du Pont Merck Pharmaceutical Company Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
US5446056A (en) * 1993-11-24 1995-08-29 The Du Pont Merck Pharmaceutical Company Isoxazoline compounds useful as fibrinogen receptor antagonists
US5563158A (en) * 1993-12-28 1996-10-08 The Dupont Merck Pharmaceutical Company Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
DE4405378A1 (de) * 1994-02-19 1995-08-24 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
US5821241A (en) * 1994-02-22 1998-10-13 Merck & Co., Inc. Fibrinogen receptor antagonists
US5756810A (en) * 1994-03-11 1998-05-26 Pharmacopeia, Inc. Process of preparing 3-nitro benzoate compounds in lower alkanol
WO1995025101A1 (fr) * 1994-03-14 1995-09-21 Merck & Co., Inc. Ethylation pyridylique des lactames
WO1995025088A1 (fr) * 1994-03-14 1995-09-21 Merck & Co., Inc. Ethylation pyridylique de derives de lactames
US5451578A (en) * 1994-08-12 1995-09-19 Merck & Co., Inc. Fibrinogen receptor antagonists
US5525617A (en) * 1994-08-24 1996-06-11 Merck & Co., Inc. Fibrinogen receptor antagonists
US5686607A (en) * 1994-09-16 1997-11-11 Merck & Co., Inc. Pyridyl ethylation of lactam derivatives
US5494921A (en) * 1994-09-16 1996-02-27 Merck & Co., Inc. Fibrinogen receptor antagonists
AU691677B2 (en) * 1994-11-01 1998-05-21 Terumo Kabushiki Kaisha Tetrahydroisoquinoline derivative and medicinal preparation containing the same
US5719144A (en) * 1995-02-22 1998-02-17 Merck & Co., Inc. Fibrinogen receptor antagonists
US5674894A (en) * 1995-05-15 1997-10-07 G.D. Searle & Co. Amidine derivatives useful as platelet aggregation inhibitors and vasodilators
ZA963391B (en) * 1995-05-24 1997-10-29 Du Pont Merck Pharma Isoxazoline fibrinogen receptor antagonists.
US6187757B1 (en) 1995-06-07 2001-02-13 Ariad Pharmaceuticals, Inc. Regulation of biological events using novel compounds
US5852045A (en) * 1995-10-19 1998-12-22 Merck & Co., Inc. Fibrinogen receptor antagonists
WO1997014417A1 (fr) * 1995-10-19 1997-04-24 Merck & Co., Inc. Antagonistes du recepteur de fibrinogene
CA2242877A1 (fr) * 1996-01-16 1997-07-24 Merck & Co., Inc. Antagonistes du recepteur integrine
US5952306A (en) * 1996-01-16 1999-09-14 Merck & Co., Inc. Integrin receptor antagonists
JP2000506524A (ja) * 1996-03-13 2000-05-30 藤沢薬品工業株式会社 フィブリノーゲン受容体拮抗剤であるＮ―［（Ｒ）―１―｛３―（４―ピペリジル）プロピオニル｝―３―ピペリジルカルボニル］―２（Ｓ）―アセチルアミノ―β―アラニン
GB2312895A (en) * 1996-05-10 1997-11-12 Merck & Co Inc Fibrinogen receptor antagonists
US5889023A (en) * 1996-05-10 1999-03-30 Merck & Co., Inc. Fibrinogen receptor antagonist
AU3404097A (en) * 1996-06-19 1998-01-07 Becton Dickinson & Company Iontophoretic delivery of cell adhesion inhibitors
US6004955A (en) * 1996-08-15 1999-12-21 Dupont Pharmaceuticals Company Cyclic carbamates and isoxazolidines as IIb/IIIa antagonists
US5900414A (en) * 1996-08-29 1999-05-04 Merck & Co., Inc. Methods for administering integrin receptor antagonists
US6211184B1 (en) * 1996-08-29 2001-04-03 Merck & Co., Inc. Integrin antagonists
US5981546A (en) * 1996-08-29 1999-11-09 Merck & Co., Inc. Integrin antagonists
EP0946178A4 (fr) * 1996-09-18 2003-05-07 Merck & Co Inc Traitement combine destine a reduire les risques de maladies cardio-vasculaires
US5978698A (en) * 1996-10-08 1999-11-02 Merck & Co., Inc. Angioplasty procedure using nonionic contrast media
US6063794A (en) 1996-10-11 2000-05-16 Cor Therapeutics Inc. Selective factor Xa inhibitors
US6369080B2 (en) 1996-10-11 2002-04-09 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6262047B1 (en) 1996-10-11 2001-07-17 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6194435B1 (en) 1996-10-11 2001-02-27 Cor Therapeutics, Inc. Lactams as selective factor Xa inhibitors
US5919792A (en) * 1996-10-30 1999-07-06 Merck & Co., Inc. Integrin antagonists
US5952341A (en) * 1996-10-30 1999-09-14 Merck & Co., Inc. Integrin antagonists
US6017925A (en) * 1997-01-17 2000-01-25 Merck & Co., Inc. Integrin antagonists
US5981584A (en) * 1997-02-06 1999-11-09 Merck & Co., Inc. Fibrinogen receptor antagonist prodrugs
NZ500353A (en) 1997-04-14 2002-02-01 Cor Therapeutics Inc Cyclic diaza compounds that are selective inhibitors of factor Xa
EP0977773A1 (fr) 1997-04-14 2000-02-09 Cor Therapeutics, Inc. INHIBITEURS SELECTIFS DU FACTEUR Xa
EP0975659A1 (fr) * 1997-04-14 2000-02-02 Cor Therapeutics, Inc. INHIBITEURS SELECTIFS DU FACTEUR Xa
WO1998046591A1 (fr) * 1997-04-14 1998-10-22 Cor Therapeutics, Inc. INHIBITEURS SELECTIFS DU FACTEUR Xa
US6294549B1 (en) 1997-07-23 2001-09-25 Merck & Co., Inc. Method for eliciting an αvβ5 or dual αvβ3/αvβ5 antagonizing effect
CA2297815A1 (fr) * 1997-07-31 1999-02-11 Ube Industries, Ltd. Composes amides n-acylamino acides et intermediaires utiles dans la preparation de ceux-ci
US6228854B1 (en) 1997-08-11 2001-05-08 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6333321B1 (en) 1997-08-11 2001-12-25 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6218382B1 (en) 1997-08-11 2001-04-17 Cor Therapeutics, Inc Selective factor Xa inhibitors
GB2328871A (en) * 1997-09-05 1999-03-10 Merck & Co Inc Compositions for inhibiting platelet aggregation
US6129932A (en) * 1997-09-05 2000-10-10 Merck & Co., Inc. Compositions for inhibiting platelet aggregation
GB2328873A (en) * 1997-09-08 1999-03-10 Merck & Co Inc The use of [3(R)-[2-(piperidin-4-yl)ethyl]-2-piperidone-1]acetyl-3(R)-methyl-ß-alanine for inhibiting blood platelet aggregation
AU1523199A (en) * 1997-11-26 1999-06-15 Du Pont Pharmaceuticals Company 1,3,4-thiadiazoles and 1,3,4-oxadiazoles as alphavbeta3 antagonists
US6048861A (en) 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
US6066648A (en) 1997-12-17 2000-05-23 Merck & Co., Inc. Integrin receptor antagonists
US6017926A (en) * 1997-12-17 2000-01-25 Merck & Co., Inc. Integrin receptor antagonists
US6211191B1 (en) 1997-12-17 2001-04-03 Merck & Co., Inc. Integrin receptor antagonists
US6623981B2 (en) * 1998-01-27 2003-09-23 Bristol-Myers Squibb Company Detection of patients at risk for developing integrin antagonist/agonist mediated disease states
US6984635B1 (en) 1998-02-13 2006-01-10 Board Of Trustees Of The Leland Stanford Jr. University Dimerizing agents, their production and use
WO2000000481A1 (fr) 1998-06-29 2000-01-06 Du Pont Pharmaceuticals Company Isoxazolidines et carbamates cycliques utilises comme antagonistes de iib/iiia
CA2338878A1 (fr) * 1998-08-13 2000-02-24 Merck & Co., Inc. Antagonistes de recepteurs d'integrine
CA2345210A1 (fr) 1998-11-18 2000-05-25 Prabhakar Kondaji Judhav Nouveaux antagonistes du recepteur de fibrinogene a base d'isoxazoline
US6319937B1 (en) 1998-11-18 2001-11-20 Dupont Pharmaceuticals Company Isoxazoline fibrinogen receptor antagonists
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
ATE277923T1 (de) * 1999-05-07 2004-10-15 Texas Biotechnology Corp Propansäurederivate, die die bindung von integrinen an ihre rezeptoren behindern
US6723711B2 (en) 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
CA2373937A1 (fr) 1999-06-02 2000-12-07 Merck & Co., Inc. Antagonistes du recepteur de l'alpha v integrine
US7067526B1 (en) 1999-08-24 2006-06-27 Ariad Gene Therapeutics, Inc. 28-epirapalogs
AU783158B2 (en) 1999-08-24 2005-09-29 Ariad Pharmaceuticals, Inc. 28-epirapalogs
JP2003510360A (ja) 1999-10-04 2003-03-18 メルク エンド カムパニー インコーポレーテッド インテグリン受容体拮抗薬
US6518244B2 (en) 2000-03-09 2003-02-11 Intimax Corporation Combinations of heparin cofactor II agonist and platelet IIb/IIIa antagonist, and uses thereof
AR030817A1 (es) 2000-10-02 2003-09-03 Novartis Ag Derivados de diazacicloalcanodiona
US7186855B2 (en) * 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) * 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7232924B2 (en) * 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
JP4336196B2 (ja) 2001-07-18 2009-09-30 メルク エンド カムパニー インコーポレーテッド メラノコルチン受容体作動薬としての架橋ピペリジン誘導体
SI21096B (sl) * 2001-10-09 2012-05-31 Encysive Pharmaceuticals Inc Derivati karboksilne kisline ki inhibirajo vezavo integrinov na njihove receptorje
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
EP1626961B1 (fr) * 2003-05-17 2011-11-02 Korea Research Institute of Bioscience and Biotechnology Nouveaux composes 2-oxo-heterocycliques et compositions pharmaceutiques contenant ces composes
JP2009503020A (ja) 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 肥満症の治療におけるフリバンセリンの使用
US20070086958A1 (en) * 2005-10-14 2007-04-19 Medafor, Incorporated Formation of medically useful gels comprising microporous particles and methods of use
US20070087061A1 (en) * 2005-10-14 2007-04-19 Medafor, Incorporated Method and composition for creating and/or activating a platelet-rich gel by contact with a porous particulate material, for use in wound care, tissue adhesion, or as a matrix for delivery of therapeutic components
JP2009541443A (ja) 2006-06-30 2009-11-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 尿失禁及び関連疾患の治療のためのフリバンセリン
PE20091188A1 (es) 2007-09-12 2009-08-31 Boehringer Ingelheim Int Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen
CA2686480A1 (fr) 2008-12-15 2010-06-15 Boehringer Ingelheim International Gmbh Nouveaux sels
CN102574818B (zh) * 2009-07-30 2015-02-25 萨尔瓦特实验室股份有限公司 Apaf-1抑制剂化合物
AU2011352228B2 (en) 2010-12-27 2015-12-03 Brown University Therapeutic and diagnostic methods involving biglycan and utrophin
US11043823B2 (en) * 2017-04-06 2021-06-22 Tesla, Inc. System and method for facilitating conditioning and testing of rechargeable battery cells
US10605101B2 (en) 2017-09-12 2020-03-31 United Technologies Corporation Process of making integrally bladed rotor
US10792771B2 (en) 2017-09-12 2020-10-06 Raytheon Technologies Corporation Method of making integrally bladed rotor
US10561736B1 (en) 2019-01-09 2020-02-18 Spiral Therapeutics, Inc. Apoptosis inhibitor formulations for prevention of hearing loss

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2549999A1 (de) * 1975-11-07 1977-05-12 Boehringer Mannheim Gmbh Piperidin-derivate und verfahren zu ihrer herstellung
FR2334358A1 (fr) * 1975-12-12 1977-07-08 Sogeras Nouveaux medicaments derives de l'indole
US4064125A (en) * 1976-10-29 1977-12-20 E. R. Squibb And Sons, Inc. Substituted amides having antiinflammatory activity
IL60129A0 (en) * 1979-05-23 1980-07-31 Wuelfing J Kg Phenylsulphonamide derivatives,their preparation and pharmaceutical compositions containing them
KR880007441A (ko) * 1986-12-11 1988-08-27 알렌 제이.스피겔 스피로-치환된 글루타르아미드 이뇨제
US4879313A (en) * 1988-07-20 1989-11-07 Mosanto Company Novel platelet-aggregation inhibitors
US5039805A (en) * 1988-12-08 1991-08-13 Hoffmann-La Roche Inc. Novel benzoic and phenylacetic acid derivatives
US5084466A (en) * 1989-01-31 1992-01-28 Hoffmann-La Roche Inc. Novel carboxamide pyridine compounds which have useful pharmaceutical utility
CA2008116C (fr) * 1989-02-23 2001-11-20 Thomas Weller Derives de glycine
NZ234264A (en) * 1989-06-29 1993-05-26 Warner Lambert Co N-substituted cycloalkyl and polycycloalkyl alpha-substituted trp-phe- and phenethylamine derivatives, and pharmaceutical compositions
US5064814A (en) * 1990-04-05 1991-11-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Anti-thrombotic peptide and pseudopeptide derivatives
IL99537A (en) * 1990-09-27 1995-11-27 Merck & Co Inc Fibrinogen receptor antagonists and pharmaceutical preparations containing them
NZ239876A (en) * 1990-09-27 1993-12-23 Merck & Co Inc Glycyl-b-alanine derivatives and pharmaceutical compositions thereof.

Also Published As

Publication number Publication date
DE69230013T2 (de) 2000-04-27
HUT68769A (en) 1995-07-28
US5455243A (en) 1995-10-03
EP0512831B1 (fr) 1999-09-22
US5281585A (en) 1994-01-25
MXPA92002103A (es) 2005-08-25
JPH069525A (ja) 1994-01-18
CA2068064C (fr) 2001-01-02
YU47992A (sh) 1995-03-27
NO933999D0 (no) 1993-11-05
CN1067883A (zh) 1993-01-13
FI934894A (fi) 1993-11-05
FI934894A0 (fi) 1993-11-05
AU647618B2 (en) 1994-03-24
ATE184874T1 (de) 1999-10-15
DE69230013D1 (de) 1999-10-28
AU1611192A (en) 1992-11-12
HU9303145D0 (en) 1994-01-28
IE921463A1 (en) 1992-11-18
EP0512831A1 (fr) 1992-11-11
NZ242609A (en) 1995-04-27
JP2531562B2 (ja) 1996-09-04
ES2137175T3 (es) 1999-12-16
WO1992019595A1 (fr) 1992-11-12
CA2068064A1 (fr) 1992-11-08
NO933999L (no) 1993-11-05
IL101779A0 (en) 1992-12-30
KR920021531A (ko) 1992-12-18

Similar Documents

Publication Publication Date Title
BG98194A (bg) Фибриногенни рецепторни антагонисти
EP0512829B1 (fr) Antagonistes des récepteurs fibrinogéniques
EP0478362B1 (fr) Antagonistes des récepteurs fibrinogéniques
US5264420A (en) Fibrinogen receptor antagonists
CZ359997A3 (cs) Pětičlenné heterocyklické sloučeniny jako inhibitory adheze leukocytů a antagonisté VLA-4 a farmaceutický přípravek, který je obsahuje
CZ134296A3 (en) Piperidine, pyrrolidine and hexahydro-1h-azepine derivatives, process of their preparation and pharmaceutical compositions containing thereof
PL188042B1 (pl) Nowe pochodne dioksoimidazolidyny, środek farmaceutyczny i zastosowanie pochodnych dioksoimidazolidyny
JPH07116144B2 (ja) フィブリノーゲン受容体拮抗薬
JPH10503204A (ja) トロンビン阻害剤
JPH0517498A (ja) フイブリノーゲンレセプター拮抗剤
JP2002520382A (ja) インテグリン阻害剤としてのジアシルヒドラジン誘導体
JPH10511359A (ja) フィブリノゲン受容体拮抗物質
JPH07501057A (ja) フィブリノーゲン・アンタゴニスト用ｃ８−環状ペプチド模倣体
RU2240326C2 (ru) Новые пятичленные гетероциклы, их получение, их применение и содержащие их фармацевтические препараты
SK102495A3 (en) Fibrinogen receptor antagonists and pharmaceutical agents containing them
JPH10511357A (ja) フィブリノゲン受容体拮抗物質
KR100328287B1 (ko) 항혈전제화합물로서의니페코트산유도체
JPH02300199A (ja) レトロウイルスプロテアーゼ阻害剤
DE19850131A1 (de) Chromenon- und Chromanonderivate
SK7452001A3 (en) Vitronectin receptor antagonist
JPH08508501A (ja) フィブリノーゲンレセプターアンタゴニスト
JPH10511356A (ja) フィブリノゲン受容体拮抗物質
US5753667A (en) 1-oxo-2- (phenylsulphonylamino) pentylpiperidine derivatives, their preparation and their therapeutic application
CZ20032429A3 (cs) Imidazolidinové deriváty, způsob jejich přípravy a jejich použití jako protizánětlivých prostředků
LT3284B (en) Fibrinogen receptor antagonists